ArticleIndian journal of pharmacology2026
Silymarin alleviates cisplatin-induced cachexia via modulating tripartite motif containing 63 (TRIM63) and myogenin.
Article in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCachexia is one of the major chemotherapy-induced adverse effects, characterized by gradual depletion of muscle mass. Currently, there is no specific treatment for cachexia. This study aims to evaluate the role of silymarin in attenuating muscle wasting in a model of cisplatin-induced cachexia. MATERIALS AND
methodsFemale Swiss albino mice were divided into three groups (n = 6) and received the treatment according to their group for 7 days: NC (Normal Control, receiving normal saline), CP (Cisplatin, receiving cisplatin 3 mg/kg i.p.) and SY+CP (Silymarin+Cisplatin, receiving silymarin 100 mg/kg orally two hours before cisplatin 3mg/kg i.p). Body weight, muscle weight, tumor necrosis factor alpha (TNF-α), and GSH levels were measured, and muscle histopathological studies were performed.
resultsSilymarin prevented cisplatin-induced damage in the triceps, quadriceps, and gastrocnemius muscles. Cisplatin administration altered tissue architecture and decreased the size and cross-sectional area of all three muscle fibers, which were significantly restored in the silymarin-treated group. Muscle tissue homogenates from the silymarin-treated group exhibited higher levels of reduced glutathione compared to the cisplatin group. The elevated serum TNF-α levels in the cisplatin group were decreased from 183 ± 1.66 pg/mL to 117.40 ± 10.47 pg/mL in the silymarin-treated mice. Tripartite motif-containing 63 (TRIM63), a muscle atrophy marker, was upregulated, and myogenin, a marker of myogenesis, was decreased by cisplatin, and the expression of both markers was reversed upon silymarin treatment.
conclusionsSilymarin attenuates cisplatin-induced cachexia through TRIM63 suppression, myogenin restoration, and reduced oxidative and inflammatory stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.